Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

25.79 +2.76 (+11.98%)
Streaming Delayed Price Updated: 12:07 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,162,089
Open 22.99
Bid (Size) 25.76 (500)
Ask (Size) 25.82 (300)
Prev. Close 23.03
Today's Range 22.80 - 25.97
52wk Range 4.300 - 40.37
Shares Outstanding 45,711,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 
Via Stocktwits
News headline image
Here's Why This Biotechnology Skyrocketed by 439% in December ↗
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment. 
Via The Motley Fool

Performance

YTD
-8.9%
-8.9%
1 Month
+6.6%
+6.6%
3 Month
+357.3%
+357.3%
6 Month
+236.2%
+236.2%
1 Year
+72.9%
+72.9%

More News

Read More
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% ↗
Via Stocktwits
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗
Via Stocktwits
Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗
Via Stocktwits
News headline image
Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Preview: Capricor Therapeutics's Earnings ↗
Via Benzinga
Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗
Via Stocktwits
News headline image
Why Did Capricor Therapeutics Stock Skyrocket Today? ↗
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗
Via Benzinga
News headline image
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗
Via Stocktwits
News headline image
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Capricor Therapeutics Stock Is Surging Today ↗
Via Benzinga
News headline image
Gapping stocks in Thursday's session ↗
Via Chartmill
News headline image
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Capricor Therapeutics, Inc. - Common Stock publicly traded?
Yes, Capricor Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Capricor Therapeutics, Inc. - Common Stock trade on?
Capricor Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Capricor Therapeutics, Inc. - Common Stock?
The ticker symbol for Capricor Therapeutics, Inc. - Common Stock is CAPR on the Nasdaq Stock Market
What is the current price of Capricor Therapeutics, Inc. - Common Stock?
The current price of Capricor Therapeutics, Inc. - Common Stock is 25.79
When was Capricor Therapeutics, Inc. - Common Stock last traded?
The last trade of Capricor Therapeutics, Inc. - Common Stock was at 02/18/26 12:07 PM ET
What is the market capitalization of Capricor Therapeutics, Inc. - Common Stock?
The market capitalization of Capricor Therapeutics, Inc. - Common Stock is 1.18B
How many shares of Capricor Therapeutics, Inc. - Common Stock are outstanding?
Capricor Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.